HUTCHMED (China) Limited (HCM) is in Healthcare, Drug Manufacturers - Specialty & Generic, based in Hong Kong, listed on NasdaqGS. Market cap 2.38B USD. 52-week range 9.77 to 16.33 USD. Trailing P/E 136.7. Data as of 2026-10-09.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung ...